36 subjects received a single dose of STS101, 1.0 mg DHE mesylate IM injection, and 2 mg DHE mesylate nasal spray in a randomized, 5-period crossover manner.
Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.